Cabaletta Bio (CABA) vs Fennec Pharmaceuticals (FENC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Fennec Pharmaceuticals (FENC) has outperformed Cabaletta Bio (CABA) over the past year, gaining 15.3% versus a loss of 19.1%. Over five years, FENC leads with a +15.7% price change compared with -83.9% for CABA. Fennec Pharmaceuticals is the larger company by market cap ($376.3 million vs $328.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CABA | FENC |
|---|---|---|
| Share price | $1.94 | $10.73 |
| Market cap | $328.92M | $376.27M |
| 1-day change | -0.51% | +0.94% |
| YTD return | -10.96% | +38.05% |
| 1-year return | -19.09% | +15.29% |
| 5-year return | -83.93% | +15.67% |
| Forward P/E | — | 11.32 |
| EPS (TTM) | $-1.51 | $-0.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.23 | $13.25 |
| 52-week low | $1.83 | $5.65 |
| Distance from 52-week high | -54.14% | -19.02% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +582.99% | +64.68% |
| Average volume | 4.67M | 193.13K |
| Shares outstanding | 169.55M | 35.07M |
| Employees | 154 | 35 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FENC has outperformed CABA by 34.4 percentage points over the past year.
About Cabaletta Bio
CABA stock →Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 154 employees
About Fennec Pharmaceuticals
FENC stock →Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
CABA vs FENC FAQ
Which is bigger, Cabaletta Bio or Fennec Pharmaceuticals?
Fennec Pharmaceuticals (FENC) is larger, with a market capitalization of $376.27M compared with $328.92M for Cabaletta Bio (CABA).
Which stock has performed better over the past year, CABA or FENC?
FENC returned +15.29% over the past 12 months, compared with -19.09% for CABA (price return, excluding dividends). Past performance does not predict future results.
Are Cabaletta Bio and Fennec Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.